MedTrace Logo

Autoantibodies and Direct-acting Antivirals

NCT03566966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2023-12-05

No results posted yet for this study

Summary

The investigators assessed non-organ-specific antibodies before and 24 weeks after the end of therapy with direct-acting antivirals, in order to better clarify the clinical relevance of these antibodies in terms of treatment response and prognostic value.

To achieve this goal patients with hepatitis C virus related advanced liver disease, with detectable circulating autoantibodies on at least two determinations before treatment, were enrolled.

Conditions

  • Viral Hepatitis C
  • Therapy Adverse Effect

Interventions

BIOLOGICAL

Non-organ-specific Ab positive

Antiviral administration and evaluation of SVR24 and side effects

BIOLOGICAL

Non-organ-specific Ab negative

direct-acting antiviral agents

Sponsors & Collaborators

  • University of Bari

    lead OTHER

Principal Investigators

  • Alfredo Di Leo, MD, PhD · University of Bari

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2016-08-31
Completion
2017-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566966 on ClinicalTrials.gov